Search Results - "Mann, Helen"

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer by Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

“…The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression…”
Get full text

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer by Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Get full text

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component by Yang, James Chih-Hsin, Ahn, Myung-Ju, Kim, Dong-Wan, Ramalingam, Suresh S, Sequist, Lecia V, Su, Wu-Chou, Kim, Sang-We, Kim, Joo-Hang, Planchard, David, Felip, Enriqueta, Blackhall, Fiona, Haggstrom, Daniel, Yoh, Kiyotaka, Novello, Silvia, Gold, Kathryn, Hirashima, Tomonori, Lin, Chia-Chi, Mann, Helen, Cantarini, Mireille, Ghiorghiu, Serban, Jänne, Pasi A

“…Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm)…”
Get full text

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study by Goss, Glenwood, Dr Prof, Tsai, Chun-Ming, Prof, Shepherd, Frances A, Prof, Bazhenova, Lyudmila, Prof, Lee, Jong Seok, MD, Chang, Gee-Chen, MD, Crino, Lucio, MD, Satouchi, Miyako, MD, Chu, Quincy, MD, Hida, Toyoaki, MD, Han, Ji-Youn, Prof, Juan, Oscar, MD, Dunphy, Frank, Prof, Nishio, Makoto, MD, Kang, Jin-Hyoung, MD, Majem, Margarita, MD, Mann, Helen, MSc, Cantarini, Mireille, MD, Ghiorghiu, Serban, MD, Mitsudomi, Tetsuya, Prof

“…Summary Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor…”
Get full text

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection by Wu, Yi-Long, Herbst, Roy S., Mann, Helen, Rukazenkov, Yuri, Marotti, Marcelo, Tsuboi, Masahiro

“…Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after…”
Get full text

Delivery of nonbiologically-compatible membrane protein constructs to mammalian cells for functional characterization by Van Horn, Wade D., Mann, Helen F., Shah, Karan H., Luu, Dustin D., Pratt, Aerial M., Bennett, Cade F., Clowes, Katherine R., Sanders, Charles R.

Get full text

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer by Ledermann, Jonathan A, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Bennett, Bryan, Parry, David, Spencer, Stuart, Mann, Helen, Matulonis, Ursula

“…Background: Maintenance monotherapy with the poly(ADP-ribose) polymerase inhibitor olaparib significantly prolongs progression-free survival over placebo in…”
Get full text

Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues by Veldhuizen, Jaimeson, Mann, Helen F, Karamanova, Nina, Van Horn, Wade D, Migrino, Raymond Q, Brafman, David, Nikkhah, Mehdi

“…Long QT syndrome (LQTS) is a cardiovascular disease characterized by QT interval prolongation that can lead to sudden cardiac death. Many mutations with…”
Get full text

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab by Dey, Agnish, Austin, Matthew, Kluger, Harriet M., Trunova, Nataliya, Mann, Helen, Shire, Norah, Morgan, Claire, Zhou, Diansong, Mugundu, Ganesh M.

“…Purpose Immune-mediated adverse events (imAEs) may be associated with response to immune checkpoint inhibitors. We assessed the relationship between imAE…”
Get full text

Outcomes of expedited rotator cuff surgery in injured workers: Impact of pathology on readiness for return to work by Singh, Gargi, Mann, Helen, Razmjou, Helen

“…Objectives: The objectives of this study were to (1) examine the overall recovery and satisfaction following an expedited rotator cuff (RC) decompression or…”
Get full text

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials by Ye, Jiabu, Yu, Binbing, Mann, Helen, Sabin, Antony, Szijgyarto, Zsolt, Wright, David, Mukhopadhyay, Pralay, Massacesi, Cristian, Ghiorghiu, Serban, Iacona, Renee

“…We assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on the statistical analysis of time-to-event outcomes in late-phase oncology trials…”
Get full text

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer by HANRAHAN, Emer O, RYAN, Anderson J, MANN, Helen, KENNEDY, Sarah J, LANGMUIR, Peter, NATALE, Ronald B, HERBST, Roy S, JOHNSON, Bruce E, HEYMACH, John V

“…Purpose: Vandetanib [vascular endothelial growth factor (VEGF) receptor/epidermal growth factor receptor/RET inhibitor] has shown improvements in…”
Get full text

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study by Ouwens, Mario, Darilay, Annie, Zhang, Yiduo, Mukhopadhyay, Pralay, Mann, Helen, Ryan, James, Dennis, Phillip A.

“…Historically, the standard of care for patients with unresectable, Stage III non–small cell lung cancer had been concurrent chemoradiotherapy. However,…”
Get full text

The validation of published utility mapping algorithms: An example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer by Gregory, Joanne, Dyer, Matthew, Hoyle, Christopher, Mann, Helen, Hatswell, Anthony J

“…Background: Mapping algorithms can be used to generate health state utilities when a preference-based instrument is not included in a clinical study. Our aim…”
Get full text

Effectiveness of a Multidisciplinary Rehabilitation Program Following Shoulder Injury by Davis, Rachel, Razmjou, Helen, Singh, Gargi, Savona, Alicia, Hopcroft, Lisa, Edmonds, Cathryn, Mann, Helen, Boccia, Kristina, Bean, Andrea, Lin, Tukata, Leming, Kyle

“…Background: Shoulder injuries in working age adults result in a major cost to the health care system. The purpose of this study was to examine the…”
Get full text

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial by Lee, Chee Khoon, Novello, Silvia, Rydén, Anna, Mann, Helen, Mok, Tony

“…Purpose Capturing patient-reported outcome data is important for evaluating the overall clinical benefits of new cancer therapeutics. We assessed self-reported…”
Get full text

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer by Heymach, John V., Harpole, David, Mitsudomi, Tetsuya, Taube, Janis M., Galffy, Gabriella, Hochmair, Maximilian, Winder, Thomas, Zukov, Ruslan, Garbaos, Gabriel, Gao, Shugeng, Kuroda, Hiroaki, Ostoros, Gyula, Tran, Tho V., You, Jian, Lee, Kang-Yun, Antonuzzo, Lorenzo, Papai-Szekely, Zsolt, Akamatsu, Hiroaki, Biswas, Bivas, Spira, Alexander, Crawford, Jeffrey, Le, Ha T., Aperghis, Mike, Doherty, Gary J., Mann, Helen, Fouad, Tamer M., Reck, Martin

“…Patients with resectable non–small-cell lung cancer had a greater response and longer event-free survival with preoperative durvalumab plus chemotherapy and…”
Get full text

Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9) by Barlesi, Fabrice, Goldberg, Sarah B., Mann, Helen, Gopinathan, Aarthi, Newton, Michael David, Aggarwal, Charu

“…TPS8610 Background: Based on the findings of the phase 3 PACIFIC trial, durvalumab as consolidation therapy is the standard of care for patients with…”
Get full text

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer by Mok, Tony S, Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C, Kim, Hye R, Ramalingam, Suresh S, Shepherd, Frances A, He, Yong, Akamatsu, Hiroaki, Theelen, Willemijn S.M.E, Lee, Chee K, Sebastian, Martin, Templeton, Alison, Mann, Helen, Marotti, Marcelo, Ghiorghiu, Serban, Papadimitrakopoulou, Vassiliki A

“…In a randomized trial involving patients with non–small-cell lung cancer with mutant EGFR (T790M) in whom a tyrosine kinase inhibitor had failed, osimertinib…”
Get full text

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC by Naidoo, Jarushka, Antonia, Scott, Wu, Yi-Long, Cho, Byoung Chul, Thiyagarajah, Piruntha, Mann, Helen, Newton, Michael, Faivre-Finn, Corinne

“…Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after…”
Get more information